drugset / Trial / NCT01280695
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
Timeline
- Start
- 2011-02
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSDC-0602 | Unknown | 100 mg | — |
| Subject | MSDC-0602 | Unknown | 250 mg | — |
| Subject | MSDC-0602 | Unknown | 500 mg | — |
| Comparator | Pioglitazone | Small molecule | 45 mg | — |